Share:
Share this content in WeChat
X
• Clinical Article •
Application value of APT imaging combined with T2-FLAIR in non-contrast-enhanced diffuse gliomas
WANG Lingfei  CHEN Longhua  LU Yu  JIA Peng  ZHANG Wu  YUE Yiming  LI Wen 

DOI:10.12015/issn.1674-8034.2026.11.009.


[Abstract] Objective To investigate the clinical value of amide proton transfer (APT) imaging combined with T2 fluid-attenuated inversion recovery (T2-FLAIR) sequence in grading diagnosis and prediction of isocitrate dehydrogenase (IDH) genotyping of non-enhancing diffuse gliomas, so as to provide non-invasive imaging evidence for precise diagnosis and treatment of such lesions.Materials and Methods A total of 120 patients with pathologically confirmed non-enhancing diffuse gliomas in our hospital from January 2021 to March 2025 were retrospectively enrolled. All patients underwent preoperative 3.0 T MRI examinations including APT and T2-FLAIR sequences. According to the World Health Organization (WHO) classification criteria, patients were divided into low-grade group (WHO grade 2, n = 56) and high-grade group (WHO grade 3-4, n = 64). Based on postoperative pathological IDH genotyping results, patients were classified into IDH-mutant group (n = 72) and IDH-wild-type group (n = 48). Two senior radiologists performed double-blinded image analysis. The APT value and relative signal intensity (rSI) of T2-FLAIR were measured and calculated, and the T2-FLAIR mismatch sign was assessed. Intra-class correlation coefficient (ICC) was used to evaluate inter-observer agreement. Independent-samples t-test and χ2-test were adopted to compare imaging parameters among groups with different pathological grades and IDH genotypes. Receiver operating characteristic (ROC) curves were plotted to assess the diagnostic efficacy of single and combined imaging parameters.Results The intraclass correlation coefficient (ICC) values for APT value, T2 fluid-attenuated inversion recovery (T2-FLAIR) relative signal intensity (rSI), and maximum tumor diameter measured by two radiologists were 0.89, 0.92, and 0.90, respectively, indicating excellent inter-observer consistency. The APT value, T2-FLAIR rSI, and maximum tumor diameter were significantly higher in the high-grade glioma group than in the low-grade group (t = 18.723, 15.689, and 19.871, all P < 0.001). The APT value was significantly higher in the isocitrate dehydrogenase (IDH) wild-type group than in the IDH-mutant group (t = 17.652, P < 0.001), while the positive rate of the T2-FLAIR mismatch sign was significantly lower in the wild-type group (χ2 = 28.741, P < 0.001). The combination of APT value and T2-FLAIR rSI yielded an area under the curve (AUC) of 0.942 (95% CI: 0.891 to 0.974) for diagnosing high-grade glioma, with a sensitivity of 90.63%, a specificity of 87.50%, and a cut-off value of 2.71, which was significantly superior to that of each single parameter. Furthermore, the combined model of APT value and T2-FLAIR mismatch sign achieved an AUC of 0.915 (95% CI: 0.856 to 0.953) for predicting IDH wild-type glioma, with a sensitivity of 85.42%, a specificity of 88.89%, and a cut-off value of 2.68, showing better diagnostic performance than individual indicators.Conclusions The combination of APT imaging and T2-FLAIR sequence integrates molecular metabolic and morphological information with complementary advantages. It can significantly improve the accuracy of grading diagnosis and the predictive performance of IDH genotyping for non-enhancing diffuse gliomas, and provide reliable non-invasive imaging evidence for individualized clinical treatment strategies.
[Keywords] glioma, diffuse;magnetic resonance imaging;amide proton transfer imaging;T2 fluid-attenuated inversion recovery sequence;grading diagnosis;isocitrate dehydrogenase genotyping

WANG Lingfei   CHEN Longhua   LU Yu*   JIA Peng   ZHANG Wu   YUE Yiming   LI Wen  

Department of MRI, the First Affiliated Hospital of Nanyang Medical College, Nanyang 473000, China

Corresponding author: LU Y, E-mail: wangef20000@163.com

Conflicts of interest   None.

Received  2026-04-21
Accepted  2026-09-30
DOI: 10.12015/issn.1674-8034.2026.11.009
DOI:10.12015/issn.1674-8034.2026.11.009.

[1]
ZHU Q Q, TANG W X. MRI and pathological features of H3K27-altered diffuse midline glioma[J]. Zhejiang Pract Med, 2025, 30(6): 532-535. DOI: 10.16794/j.cnki.cn33-1207/r.2025.06.020.
[2]
BAO H, ZHAO Q R, YE J J, et al. Radiomics based on contrast-enhanced T2-FLAIR images for predicting IDH1 genotype in diffuse gliomas[J]. J Pract Radiol, 2026, 42(3): 359-363. DOI: 10.3969/j.issn.1002-1671.2026.03.005.
[3]
WANG H T, TIAN C S, ZHU Z Y, et al. Value of habitat analysis based on diffusion-weighted imaging in evaluating isocitrate dehydrogenase mutation status of adult diffuse gliomas[J]. Chin J Magn Reson Imaging, 2026, 17(3): 15-21. DOI: 10.12015/issn.1674-8034.2026.03.003.
[4]
DEMIREL E, DILEK O. T2-FLAIR digital subtraction radiomics versus neuroradiologist visual assessment for differentiating IDH-mutant astrocytomas from other non-enhancing low-grade gliomas: An externally validated machine learning study[J]. Neuroradiology, 2026, 68(7): 2005-2016. DOI: 10.1007/S00234-026-04025-5.
[5]
ZHOU J, ZHANG L, CHEN Y, et al. Amide proton transfer imaging in brain tumors:technical advances and clinical applications[J]. Magn Reson Med, 2021, 86(3): 1648-1667. DOI: 10.1002/mrm.28698.
[6]
LI Y, WANG X, HAN M, et al. Combined APT and T2-FLAIR imaging for grading of non-enhancing diffuse gliomas[J]. J Magn Reson Imaging, 2022, 56(2): 568-577. DOI: 10.1002/jmri.28065.
[7]
YAN H, PARSONS D W, JIN G, et al. IDH1 and IDH2 mutations in gliomas[J]. N Engl J Med, 2009, 360(8): 765-773. DOI: 10.1056/NEJMoa0808710.
[8]
ZHANG H, LI F, WANG J, et al. APT imaging for predicting IDH genotype in non-enhancing diffuse gliomas:a meta-analysis[J]. Quant Imaging Med Surg, 2023, 13(5): 3245-3258. DOI: 10.21037/qims-22-1026.
[9]
PARK S J, KIM E Y, KANG S H, et al. T2-FLAIR mismatch sign:a reliable marker for IDH-mutant, 1p/19q non-co-deleted astrocytoma[J]. Neuroradiology, 2021, 63(3): 369-377. DOI: 10.1007/s00234-020-02568-9.
[10]
WANG Y Y. Prediction of IDH mutation status in adult diffuse gliomas based on modified T2-FLAIR mismatch sign[D]. Xi'an: Air Force Medical University of PLA, 2024. DOI: 10.27002/d.cnki.gsjyu.2024.000419.
[11]
BRANDES A A, TOSONI A, FRANCESCHI E, et al. Management of diffuse low-grade gliomas in adults[J/OL]. Lancet Oncol, 2021, 22(6): e268-e279 [2026-04-21]. https://doi.org/10.1016/S1470-2045(21)00067-4. DOI: 10.1016/S1470-2045(21)00067-4.
[12]
CHEN W, LIU X, ZHANG Y, et al. Amide proton transfer imaging correlates with histological grade and Ki-67 index in diffuse gliomas[J/OL]. Clin Radiol, 2022, 77 (1): e1-e7 [2026-04-21]. https://doi.org/10.1016/j.crad.2021.06.018. DOI: 10.1016/j.crad.2021.06.018.
[13]
FU Y, WANG L, CHEN X, et al. APT imaging for grading of non-enhancing diffuse gliomas:comparison with conventional MRI and diffusion-weighted imaging[J]. J Comput Assist Tomogr, 2020, 44 (6): 902-908. DOI: 10.1097/RCT.0000000000000964.
[14]
VAN ZIJL P C, ZHANG Y. Chemical exchange saturation transfer MRI: principles and applications[J]. Magn Reson Med, 2012, 67(5): 1362-1382. DOI: 10.1002/mrm.24315.
[15]
LIU Y, MA J, ZHANG H, et al. Correlation between APT values and Ki-67 proliferation index in diffuse gliomas:a systematic review and meta-analysis[J]. J Neurooncol, 2023, 113 (3): 467-476. DOI: 10.1007/s11060-023-04068-6.
[16]
MURTAZA Z, KAMALIAN N, KALKANIS S N. Role of advanced MRI in the diagnosis and management of diffuse gliomas[J/OL]. Surg Neurol Int, 2022, 13: 863 [2026-04-21]. https://doi.org/10.4103/sni.sni_766_22. DOI: 10.4103/sni.sni_766_22.
[17]
KIM M J, CHO J H, KIM H S, et al. T2-FLAIR relative signal intensity as a predictor of histological grade in non-enhancing diffuse gliomas[J]. J Neuroradiol, 2021, 48 (4): 257-263. DOI: 10.1016/j.neurad.2020.09.006.
[18]
ZHANG Y, ZHOU J, CHEN Y, et al. ROI placement strategies for APT imaging in brain tumors:impact on measurement variability and diagnostic performance[J]. Magn Reson Imaging, 2022, 88: 113-120. DOI: 10.1016/j.mri.2022.05.004.
[19]
LI X, WANG Y, ZHANG L, et al. APT imaging in non-enhancing diffuse gliomas:value in distinguishing low-grade from high-grade tumors[J/OL]. Eur J Radiol Open, 2023, 10: 100464 [2026-04-21]. https://doi.org/10.1016/j.ejro.2023.100464. DOI: 10.1016/j.ejro.2023.100464.
[20]
SHIROTA M, NITTA M, SAITOU T, et al. NI-16 Verification of APT image and relationship with T2/FLAIR mismatch sign in WHO2016 brain tumor pathology classification[J]. Neuro-Oncol Adv, 2021, 3(Suppl 6): vi21. DOI: 10.1093/noajnl/vdab159.078.
[21]
WANG J, LI F, ZHANG H, et al. Visual assessment of APT and T2-FLAIR images for rapid grading of non-enhancing diffuse gliomas[J]. Clin Imaging, 2023, 89: 188-193. DOI: 10.1016/j.clinimag.2023.02.012.
[22]
CAIRNCROSS J G, UEKI K, ZLATESCU M C, et al. IDH mutation status as a predictor of outcome in glioblastoma[J]. N Engl J Med, 2013, 369(21): 1984-1992. DOI: 10.1056/NEJMoa1302121.
[23]
STUPP R, HEGI M E, MASON W P, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study:5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10(5): 459-466. DOI: 10.1016/S1470-2045(09)70089-2.
[24]
SWANSON K R, GRAHAM C H, MAHER E A, et al. Metabolic reprogramming in IDH-mutant gliomas[J]. Oncogene, 2018, 37(46): 5941-5950. DOI: 10.1038/s41388-018-0518-4.
[25]
CHO S, KIM B S, KIM J H, et al. APT imaging reflects metabolic alterations in IDH-mutant gliomas[J]. AJNR Am J Neuroradiol, 2022, 43(5): 616-622. DOI: 10.3174/ajnr.A7602.
[26]
KIM E Y, PARK S J, KANG S H, et al. T2-FLAIR mismatch sign in IDH-mutant astrocytoma:an update on diagnostic utility and clinical significance[J]. J Neurooncol, 2022, 158(2): 307-314. DOI: 10.1007/s11060-022-04026-9.
[27]
LATHORIA K, UMDOR B S, PATRICK S, et al. Oncometabolite D-2-hydroxyglutarate regulates actin dynamics and nuclear homeostasis in IDH1-mutant glioma[J/OL]. Cellular Signalling, 2026: 112449 [2026-04-21]. https://doi.org/10.1016/J.CELLSIG.2026.112449. DOI: 10.1016/J.CELLSIG.2026.112449.
[28]
LI M, ZHANG Y, WANG X, et al. Combined APT imaging and T2-FLAIR mismatch sign for predicting IDH genotype in non-enhancing diffuse gliomas[J]. J Magn Reson Imaging, 2023, 58(3): 892-900. DOI: 10.1002/jmri.28756.
[29]
LUCIA N, MORITZ Z, STEFANO C. APT weighted imaging in diffuse gliomas[J/OL]. BJR Open, 2023, 5(1): 20230025 [2026-04-21]. https://doi.org/10.1259/bjro.20230025. DOI: 10.1259/bjro.20230025.
[30]
DONG L, CHEN H, DAI G, et al. Grading of glioma and prediction of IDH mutation status via longitudinal relaxation time in rotating frame mapping on 5-T magnetic resonance imaging:added value to amide proton transfer-weighted imaging[J/OL]. Quant Imaging Med Surg, 2026, 16(3): 250 [2026-04-21]. https://doi.org/10.21037/qims-2025-aw-2294. DOI: 10.21037/qims-2025-aw-2294.
[31]
SHIROTA M, NITTA M, SAITOU T, et al. Usefulness of amide proton transfer images in the diagnosis of malignant glioma:comparison of APT images and 11C-methionine-positron emission tomography[J/OL]. Neuroradiol J, 2025 [2026-04-21]. https://doi.org/10.1177/19714009251345107. DOI: 10.1177/19714009251345107.
[32]
XU Z, PU S, WU J, et al. Hypoxia-induced BTN3A2 promotes glioma progression and chemoresistance via AKT/SP1/RAD51-mediated DNA damage[J/OL]. Cell Death Dis, 2026 [2026-04-21]. https://doi.org/10.1038/s41419-026-08729-7. DOI: 10.1038/s41419-026-08729-7.
[33]
XING Z, YU L, YU S. T2/FLAIR Mismatch Subregion as an Independent Prognostic Biomarker in IDH-Mutant and 1p/19q Noncodeletion Astrocytoma[J/OL]. AJNR Am J Neuroradiol, 2026 [2026-04-21]. https://doi.org/10.3174/ajnr.A9158. DOI: 10.3174/ajnr.A9158.
[34]
TARIQ Q, ALI A E, ARSHAD R, et al. Bridging Radiology and Pathology: ATRX Loss and T2-FLAIR Mismatch as Early Diagnostic and Prognostic Markers in Diffuse Gliomas[J]. JPMA J Pak Med Assoc, 2025, 75(12): 1986-1989. DOI: 10.47391/jpma.25-106.
[35]
CHEN S H, HUANG R S, LIN H Y, et al. Preoperative prediction of pathological grade and IDH genotype in adult-type diffuse gliomas using APT combined with DCE-MRI[J]. Radiol Pract, 2024, 39(8): 1021-1025. DOI: 10.13609/j.cnki.1000-0313.2024.08.006.
[36]
ZENG S M, HE L C. Application and prospect of amide proton transfer imaging in brain tumors[J]. J Pract Radiol, 2024, 40(9): 1553-1556. DOI: 10.3969/j.issn.1002-1671.2024.09.036.
[37]
SCHWENDNER M, SUVAK S, STEFANOWICZ S, et al. Tumor recurrence patterns in eloquent glioma after microsurgical resection and adjuvant radiochemotherapy[J/OL]. Neuro-Oncol Adv, 2026, 8(1): vdaf183 [2026-04-21]. https://doi.org/10.1093/noajnl/vdaf183. DOI: 10.1093/noajnl/vdaf183.

PREV Development and validation of an MRI radiomics model for the diagnosis of cerebral venous thrombosis
NEXT Predicting tumor shrinkage patterns after neoadjuvant therapy in breast cancer using a stacking model integrating MRI habitat analysis and intratumoral microbiota
  



Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn